Pharmasset Reports Fiscal First Quarter 2009 Financi...( LIABILITIES AND STOCKHOLDERS' EQ...)

Date:2/9/2009

========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Current portion of long-term debt $4,474,131 $2,651,592 Current portion of capital lease obligation - 41,641 Accounts payable 3,708,060 2,466,052 Accrued expenses 6,060,141 6,182,417 Deferred rent 124,462 124,463 Deferred revenue 1,857,136 1,857,136 --------- --------- Total current liabilities 16,223,930 13,323,301 DEFERRED RENT 48,421 79,793 DEFERRED REVENUE 3,404,674 3,868,965 LONG-TERM DEBT, net 18,053,545 16,522,665 ---------- ---------- Total liabilities 37,730,570 33,794,724 ---------- ---------- COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Common Stock, $0.001 par value, 100,000,000 shares authorized, 23,390,862 and 23,340,498 shares issued and outstanding at December 31, 2008 (unaudited) and September 30, 2008, respectively 23,391 23,340 Warrants to purchase 127,248 and 116,183 shares of common stock for $12.05 per share, as of December 31, 2008, (unaudited) and September 30, 2008, respectively 1,229,767 1,140,114 Additional paid-in capital 147,600,186 145,818,439 Accumulated other comprehensive (loss) income (1,515) (2,604) Accumulated deficit (130,067,341) (111,791,944)
'/>"/>

SOURCE Pharmasset, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th